In October, the FDA granted approval for a pre-filled syringe formulation of the reference product. Additionally, Novartis is looking to expand omalizumab’s indications, as it recently earned FDA’s breakthrough therapy designation in August 2018 as a treatment for food allergies.
Novartis recently announced that ligelizumab, a monoclonal antibody being investigated for the treatment of chronic spontaneous urticaria (CSU), will move on to phase 3 trials after demonstrating a clear dose-response relationship and improvements over another 1 of its older products, omalizumab (Xolair), in this cohort.
“Despite existing treatment options, too many people continue to struggle with the debilitating and potentially painful symptoms of CSU. Advancing ligelizumab to phase 3 is encouraging news for physicians and patients who have difficulty in controlling symptoms,” said Marcus Maurer, MD, professor of dermatology and allergy and director of research at the Department of Dermatology and Allergy of Charite-Universitätsmedizin in Berlin, Germany.
The trials come as welcome good news to Novartis, as the company looks to protect market share after omalizumab lost patent protection in the United States in June 2017, and in Europe in August 2017. Though omalizumab biosimilars have yet to be approved in either of the regulatory territories, at least 2 biosimilars are currently in development.
In July 2018, Glenmark Pharmaceuticals announced that its phase 1 study of GBR 310, a proposed omalizumab biosimilar, revealed similar pharmacokinetic, pharmacodynamic, safety, and immunogenicity profiles between its proposed omalizumab biosimilar and the reference Xolair.
Likewise, Sorrento Therapeutics, Inc, in collaboration with Mabtech, completed a combined phase 2 and phase 3 trial of STI-004 in China in 2016. Though the developers have not yet announced a filing of a Biologics License Application with the FDA, the potential biosimilar met its primary end point in the multicenter, randomized, double-blind, placebo-controlled trial.
Novartis, for its part, is fighting back against encroaching challengers in this therapeutic space. In October, the FDA granted approval for a pre-filled syringe formulation of the reference product. Additionally, Novartis is looking to expand omalizumab’s indications, as it recently earned FDA’s breakthrough therapy designation in August 2018 as a treatment for food allergies. In 2017, omalizumab brought in $1.75 billion in the United States alone.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.